Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) Net Income towards Common Stockholders (2016 - 2017)

Tenax Therapeutics' Net Income towards Common Stockholders history spans 8 years, with the latest figure at -$17.0 million for Q4 2017.

  • For Q4 2017, Net Income towards Common Stockholders fell 150.3% year-over-year to -$17.0 million; the TTM value through Dec 2017 reached -$9.2 million, down 148.51%, while the annual FY2025 figure was -$52.6 million, 198.62% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2017 was -$17.0 million at Tenax Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $33.9 million in Q4 2016 and bottomed at -$17.0 million in Q4 2017.
  • The 5-year median for Net Income towards Common Stockholders is $2.2 million (2014), against an average of $2.7 million.
  • The largest annual shift saw Net Income towards Common Stockholders plummeted 244.55% in 2015 before it skyrocketed 164.53% in 2017.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $6.1 million in 2013, then crashed by 33.34% to $4.1 million in 2014, then surged by 471.56% to $23.2 million in 2015, then surged by 46.08% to $33.9 million in 2016, then tumbled by 150.3% to -$17.0 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Net Income towards Common Stockholders are -$17.0 million (Q4 2017), $1.3 million (Q3 2017), and $3.0 million (Q2 2017).